Groupe la Francaise Purchases 4,118 Shares of Gilead Sciences, Inc. $GILD

Posted by Stanley Muller on Aug 1st, 2026

Gilead Sciences logo Groupe la Francaise grew its holdings in shares of Gilead Sciences, Inc. (NASDAQ:GILD – Free Report) by 12.2% in the 1st quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 37,915 shares of the biopharmaceutical company’s stock after purchasing an additional 4,118 shares during the quarter. Groupe la Francaise’s holdings in Gilead Sciences were worth $5,284,000 at the end of the most recent reporting period.

Other hedge funds also recently made changes to their positions in the company. Strategic Investment Solutions Inc. IL bought a new stake in Gilead Sciences in the fourth quarter worth about $25,000. Vermillion & White Wealth Management Group LLC boosted its stake in Gilead Sciences by 71.4% in the fourth quarter. Vermillion & White Wealth Management Group LLC now owns 204 shares of the biopharmaceutical company’s stock valued at $25,000 after acquiring an additional 85 shares during the last quarter. Quattro Advisors LLC bought a new position in shares of Gilead Sciences during the 4th quarter valued at approximately $26,000. Wealth Preservation Advisors LLC grew its position in shares of Gilead Sciences by 60.0% during the 4th quarter. Wealth Preservation Advisors LLC now owns 216 shares of the biopharmaceutical company’s stock valued at $27,000 after acquiring an additional 81 shares during the period. Finally, Ares Financial Consulting LLC purchased a new stake in shares of Gilead Sciences during the 4th quarter worth approximately $28,000. 83.67% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

A number of equities research analysts recently commented on the stock. Morgan Stanley lowered their price target on shares of Gilead Sciences from $166.00 to $165.00 and set an “overweight” rating on the stock in a report on Monday, July 27th. Truist Financial reduced their price objective on Gilead Sciences from $157.00 to $156.00 and set a “buy” rating for the company in a report on Tuesday, July 7th. Leerink Partners downgraded Gilead Sciences from an “outperform” rating to a “market perform” rating and decreased their target price for the stock from $146.00 to $127.00 in a research report on Tuesday, July 21st. Barclays lowered their target price on Gilead Sciences from $155.00 to $145.00 and set an “equal weight” rating on the stock in a research note on Wednesday. Finally, HSBC raised Gilead Sciences from a “hold” rating to a “buy” rating and upped their price target for the company from $133.00 to $155.00 in a research report on Monday, July 6th. Twenty-five investment analysts have rated the stock with a Buy rating and four have assigned a Hold rating to the company’s stock. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $157.93.

Read Our Latest Stock Report on GILD

Gilead Sciences Stock Performance

Shares of GILD stock opened at $130.21 on Friday. The stock has a market capitalization of $161.66 billion, a P/E ratio of 17.74 and a beta of 0.32. The company has a current ratio of 1.97, a quick ratio of 1.77 and a debt-to-equity ratio of 0.89. The firm’s 50 day moving average is $129.61 and its 200 day moving average is $135.87. Gilead Sciences, Inc. has a 12 month low of $108.46 and a 12 month high of $157.29.

Gilead Sciences (NASDAQ:GILD – Get Free Report) last announced its quarterly earnings results on Thursday, May 7th. The biopharmaceutical company reported $2.03 earnings per share for the quarter, beating the consensus estimate of $1.91 by $0.12. Gilead Sciences had a return on equity of 48.19% and a net margin of 30.99%.The firm had revenue of $6.96 billion for the quarter, compared to analysts’ expectations of $6.91 billion. During the same period in the prior year, the business posted $1.81 earnings per share. The company’s revenue was up 4.4% on a year-over-year basis. Gilead Sciences has set its FY 2026 guidance at -1.050–0.650 EPS. On average, sell-side analysts anticipate that Gilead Sciences, Inc. will post -0.78 earnings per share for the current year.

Gilead Sciences News Roundup

Here are the key news stories impacting Gilead Sciences this week:

Positive Sentiment: European regulators issued a positive opinion supporting expanded use of Gilead’s Trodelvy with Keytruda for certain patients with advanced triple-negative breast cancer. The potential label expansion could broaden Trodelvy’s commercial opportunity and strengthen Gilead’s oncology pipeline. Gilead Sciences Following Trodelvy Progress and a Fair Value Debate
Positive Sentiment: Several analyses remain favorable on GILD. One investment article argues that investors should “buy the distortion” ahead of second-quarter results, while another says the stock still appears inexpensive after delivering roughly 130% total return over five years. Gilead: Buy the Distortion Before Q2 Clears It Up Gilead Stock Stays Cheap on Its Five-Year Run
Neutral Sentiment: Investor attention is focused on Gilead’s second-quarter 2026 results. Preview articles highlight Wall Street expectations for revenue, earnings and operating metrics, but they do not provide a confirmed earnings surprise. Wall Street Projections for Gilead’s Q2 Metrics
Positive Sentiment: Analyst coverage remains broadly supportive, with reports noting Gilead’s market outperformance and bullish views on its prospects. However, heightened investor attention alone is not a fundamental catalyst. Do Wall Street Analysts Like Gilead Sciences Stock?
Negative Sentiment: Erste Group Bank reduced its fiscal 2027 earnings-per-share estimate for Gilead, raising concerns about the company’s future earnings growth. Erste Group Bank Cuts Gilead FY2027 EPS Estimate
Negative Sentiment: Barclays lowered its Gilead price target to $145. Although the revised target remains above the stock’s referenced trading level, the reduction signals more limited near-term upside and is likely weighing on sentiment. Barclays Lowers Gilead Price Target

Insider Activity at Gilead Sciences

In related news, CEO Daniel Patrick O’day sold 15,000 shares of the firm’s stock in a transaction dated Monday, June 1st. The stock was sold at an average price of $131.46, for a total transaction of $1,971,900.00. Following the transaction, the chief executive officer directly owned 617,567 shares of the company’s stock, valued at approximately $81,185,357.82. This trade represents a 2.37% decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Johanna Mercier sold 28,000 shares of the business’s stock in a transaction that occurred on Friday, May 15th. The stock was sold at an average price of $131.29, for a total transaction of $3,676,120.00. Following the completion of the sale, the insider owned 125,779 shares of the company’s stock, valued at approximately $16,513,524.91. The trade was a 18.21% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 67,000 shares of company stock valued at $8,687,140 over the last 90 days. 0.30% of the stock is owned by insiders.

Gilead Sciences Company Profile

(Free Report)

Gilead Sciences, Inc, founded in 1987 and headquartered in Foster City, California, is a biopharmaceutical company focused on the discovery, development and commercialization of medicines in areas of high unmet medical need. The company initially built its reputation in antiviral therapies and has since expanded into oncology, cell therapy and inflammatory diseases. Gilead operates a global research and commercial organization, conducting clinical development and selling medicines in markets around the world.

Gilead’s product portfolio is anchored by antiviral therapies for HIV and viral hepatitis.